BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, July 6, 2026
Home » Topics » Briefs » Regulatory actions

Regulatory actions
Regulatory actions RSS Feed RSS

Regulatory actions for Dec. 1, 2025

Dec. 1, 2025
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Ascendis, Astrazeneca, Beone, Novo Nordisk, Otsuka, Sun.
Read More

Regulatory actions for Dec. 1, 2025

Dec. 1, 2025
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: A2z Radiology, Boston Scientific, Cleveland Diagnostics, Mediview.
Read More

Regulatory actions for Nov. 26, 2025

Nov. 26, 2025
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Biogen, BMS, Eisai, Innovent, Novartis, Otsuka, Regeneron, Sanofi, Sarepta, Teva.
Read More

Regulatory actions for Nov. 26, 2025

Nov. 26, 2025
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: GE Healthcare.
Read More

Regulatory actions for Nov. 25, 2025

Nov. 25, 2025
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Alvotech, Avenzo, Merck.
Read More

Regulatory actions for Nov. 25, 2025

Nov. 25, 2025
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Biocomposites, Bracco Diagnostics, Collagen Matrix, Ischemaview, Rapidai, Regenity.
Read More

Regulatory actions for Nov. 25, 2025

Nov. 25, 2025
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Celltrion, Henlius, Obi Pharma.
Read More

Regulatory actions for Nov. 24, 2025

Nov. 24, 2025
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Sangamo.
Read More

Regulatory actions for Nov. 24, 2025

Nov. 24, 2025
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: BD, Ceribell, Transmural Systems, YD Bio.
Read More

Regulatory actions for Nov. 21, 2025

Nov. 21, 2025
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Accord, Advanz, Alexion, Alvotech, Amgen, Astrazeneca, Bayer, Nuvalent, Regeneron.
Read More
Previous 1 2 … 18 19 20 21 22 23 24 25 26 … 341 342 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2026.
  • CINP 2026: Prenatal and adolescent stress shape brain vulnerability

    BioWorld Science
    Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
  • Ontrack Therapeutics divulges compounds for neurodegenerative diseases

    BioWorld Science
    Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
  • Modius Spero wearable neuromodulation device

    Neurovalens granted FDA approval for PTSD therapy for US veterans

    BioWorld
    Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
  • IPO puzzle pieces

    Neuracle eyes Shanghai IPO as global BCI funding surges

    BioWorld
    Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing